Month: June 2020

TITUSVILLE, Fla., June 22, 2020 (GLOBE NEWSWIRE) — The Apple Rush Company, Inc. (US OTC PINK: APRU) (the “company”), a beverage maker, manufacturer of unique consumer brands and CBD and Kratom products and drinks, announced today that it has delivered the second order of Element C, CBD infused beverages to North Dakota.Apple Rush Company, Inc has delivered four additional pallets to our distributor in North Dakota.  This shipment was delivered Friday and deliveries to retailers will begin today. “It is exciting to see that progress has been made with Element C.  It has been well received and we are excited that it will be available in retailers now.  Our Midwest investors group has been very proactive in developing their market and we believe their success will create a model for distribution in more populous states.  CBD infused...

SANTA CLARA, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Adesto Technologies Corporation (NASDAQ: IOTS), a leading provider of innovative application-specific semiconductors and embedded systems for the IoT, announces that in connection with the pending acquisition of Adesto by Dialog Semiconductor plc (XETRA:DLG), the parties have been informed by the Committee on Foreign Investment in the United States (CFIUS) that CFIUS has completed its review of the pending acquisition and determined that there are no unresolved national security concerns with respect to the proposed transaction. The parties expect the transaction to close on June 29, 2020, subject to customary closing conditions.About Adesto Technologies Corp.Adesto Technologies Corporation (NASDAQ:IOTS) is a leading provider of innovative application-specific semiconductors...

VANCOUVER, British Columbia, June 22, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) announces that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to the Company’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company.“With the recent growth and interest in our industry, ensuring our disclosure obligations are satisfied is at the forefront of our attention.  Ensuring fulsome and timely disclosure is vital to the success of our Company, and development of our industry with the investing public.  We look forward to working with staff of the British...

– Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells –– Translational data expand on scientific rationale for both ongoing EMERGE Phase 2 trial and upcoming SELECT trial –CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the presentation of new preclinical data from its JTX-1811 program and translational data from its ongoing vopratelimab program at the American Association for Cancer Research (AACR) Virtual Annual Meeting.“The progress we have made to date with both JTX-1811, our anti-CCR8 antibody,...

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that its partner Bristol Myers Squibb presented preclinical data from BMS-986249 and BMS-986288, anti-CTLA-4 Probody therapeutics generated with CytomX’s novel Probody® technology platform. The electronic poster #4551 titled “Preclinical characterization of novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic index” was presented as part of the Therapeutic Antibodies 3 Session at the American Association of Cancer Research’s (AACR) 2020 Virtual Annual Meeting II.BMS-986249 is a Probody version of the anti-CTLA-4 antibody ipilimumab (Yervoy®). In February 2020, Bristol Myers Squibb treated the first patient in a Part 2a randomized cohort expansion in an ongoing Phase 1/2a trial of BMS-986249 in combination...

LAS VEGAS, June 22, 2020 (GLOBE NEWSWIRE) — iBrands Corporation  (OTC: IBRC) (“the Company”), a diversified holding and branding company, announces novel data suggesting that QuadraMune™ administration reduces the number and activity of immune inhibitory cells termed “myeloid suppressor cells.”In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company’s  nutraceutical manufacturer, Therapeutics Solutions International, Inc. (TSOI), described through its filed patent preliminary data suggest that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a “cancer vaccine”.  These data suggest that the nutraceutical, which is currently being tested as a preventative immune booster to protect against COVID-19[1], may have potential use...

Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulationSeborrheic dermatitis affects over 6 million U.S. patientsPhase 2 topline data anticipated early in fourth quarter of 2020The Company also announced first patient enrolled in long-term safety studyWESTLAKE VILLAGE, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced it had completed enrollment of its Phase 2 proof of concept clinical trial evaluating roflumilast foam as a potential treatment for seborrheic dermatitis.  Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective...

Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapyInhibigens alter the tumor microenvironment and drive tumor hyperprogressionInhibigens abolish both global and tumor antigen-specific T cell activityCAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new and important insights into the biology and behavior of inhibitory neoantigens (Inhibigens™)  at the American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24. The findings build on previous research presented at SITC 2019 which demonstrated that the presence of an Inhibigen in an otherwise protective immunotherapy can completely reverse anti-tumor...

SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today presented preclinical studies highlighting the potential for its lead drug candidate, repotrectinib, to increase the effectiveness of KRAS-G12C and MEK inhibitors in cancer models, and for its next-generation ALK inhibitor candidate, TPX-0131, to overcome ALK-resistant mutations.The studies were included as part of three poster presentations at today’s virtual annual meeting of the American Association for Cancer Research (AACR).“Feedback reactivation and bypass signaling may limit the efficacy of KRAS-G12C and MEK inhibitors against KRAS-driven tumors, and our encouraging preclinical data shows how repotrectinib has the potential...

UNIONDALE, N.Y., June 22, 2020 (GLOBE NEWSWIRE) — Flushing Financial Corporation (the “Company”) (Nasdaq: FFIC), the parent holding company for Flushing Bank (the “Bank”), announced today that the Bank has received funds from the FHLBNY Small Business Recovery Grant Program. These funds are intended to support the financial security and health of workers employed by organizations that have suffered a decrease in revenue as a result of the ongoing COVID-19 crisis. The Bank has begun to disburse the grant money to local small businesses and non-profit organizations in their market area.“Our participation in this grant program allows us to provide much needed support to small businesses and non-profit organizations, both customers and non-customers, in the communities we serve.” stated John R. Buran, President and CEO. “Small businesses...